Cyproheptadine
A first-generation antihistamine with additional antiserotonin and anticholinergic properties used for allergies, itching, and as an appetite stimulant. It blocks histamine H1 receptors and serotonin receptors and is sometimes used off-label for migraine prevention.
Moleküler Ağırlık
287,4000 g/mol
LogP
4,70
TPSA
3,20 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
2D Yapı
Cite this structure
Embed this structure
SMILES
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1
InChI
InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3
Molecular Formula
C21H21N
HBD / HBA
- / 1
Döndürülebilir Bağlar
0
Ağır Atomlar
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A first-generation antihistamine with additional antiserotonin and anticholinergic properties used for allergies, itching, and as an appetite stimulant. It blocks histamine H1 receptors and serotonin receptors and is sometimes used off-label for migraine prevention.
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Yes, Cyproheptadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL516. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2913. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cyproheptadine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cyproheptadine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cyproheptadine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cyproheptadine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cyproheptadine"></drugfyi-drug>